GenMark Diagnostics, Inc. (GNMK) to Release Earnings on Wednesday
GenMark Diagnostics, Inc. (NASDAQ:GNMK) is scheduled to be releasing its earnings data before the market opens on Wednesday, November 1st. Analysts expect GenMark Diagnostics to post earnings of ($0.26) per share for the quarter.
GenMark Diagnostics (NASDAQ:GNMK) last posted its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.05). GenMark Diagnostics had a negative return on equity of 109.89% and a negative net margin of 111.96%. The business had revenue of $12.36 million during the quarter, compared to analysts’ expectations of $12.44 million. During the same quarter in the prior year, the firm earned ($0.30) EPS. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. On average, analysts expect GenMark Diagnostics to post $-1.06 EPS for the current fiscal year and $-0.62 EPS for the next fiscal year.
GenMark Diagnostics, Inc. (GNMK) opened at 7.82 on Wednesday. The stock’s market cap is $427.50 million. The stock has a 50 day moving average price of $9.16 and a 200 day moving average price of $11.20. GenMark Diagnostics, Inc. has a 1-year low of $7.68 and a 1-year high of $13.67.
In other GenMark Diagnostics news, SVP Eric Stier sold 2,750 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $9.60, for a total transaction of $26,400.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Jennifer Anne Williams sold 38,681 shares of the stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $9.08, for a total value of $351,223.48. Following the sale, the senior vice president now directly owns 155,889 shares in the company, valued at $1,415,472.12. The disclosure for this sale can be found here. Insiders sold a total of 58,736 shares of company stock valued at $544,341 in the last 90 days. 7.50% of the stock is currently owned by company insiders.
Several analysts have recently commented on the company. BidaskClub upgraded GenMark Diagnostics from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Canaccord Genuity restated a “buy” rating and issued a $14.00 target price (down previously from $17.00) on shares of GenMark Diagnostics in a research note on Monday, August 7th. Cowen and Company restated an “outperform” rating and issued a $17.00 target price on shares of GenMark Diagnostics in a research note on Wednesday, August 2nd. Needham & Company LLC restated a “buy” rating and issued a $15.00 target price (down previously from $17.00) on shares of GenMark Diagnostics in a research note on Wednesday, September 13th. Finally, BTIG Research restated a “buy” rating and issued a $13.00 target price on shares of GenMark Diagnostics in a research note on Thursday, August 31st. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $14.40.
GenMark Diagnostics Company Profile
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.